---
layout: default
title: Multimodal Posterior Sampling-based Uncertainty in PD-L1 Segmentation from H&E Images
---

# Multimodal Posterior Sampling-based Uncertainty in PD-L1 Segmentation from H&E Images

**arXiv**: [2511.11486v1](https://arxiv.org/abs/2511.11486) | [PDF](https://arxiv.org/pdf/2511.11486.pdf)

**ä½œè€…**: Roman Kinakh, Gonzalo R. RÃ­os-MuÃ±oz, Arrate MuÃ±oz-Barrutia

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºåŸºäºŽå¤šæ¨¡æ€åŽéªŒé‡‡æ ·çš„è´å¶æ–¯åˆ†å‰²æ¡†æž¶ï¼Œä»ŽH&Eå›¾åƒé¢„æµ‹PD-L1è¡¨è¾¾ä»¥è§£å†³èµ„æºå¯†é›†é—®é¢˜ã€‚**

**å…³é”®è¯**: `è´å¶æ–¯åˆ†å‰²` `å¤šæ¨¡æ€åŽéªŒé‡‡æ ·` `PD-L1è¡¨è¾¾é¢„æµ‹` `H&Eå›¾åƒåˆ†æž` `ä¸ç¡®å®šæ€§ä¼°è®¡`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šPD-L1è¡¨è¾¾è¯„ä¼°ä¾èµ–èµ„æºå¯†é›†çš„å…ç–«ç»„åŒ–æ–¹æ³•ï¼Œéœ€æ›´é«˜æ•ˆæ›¿ä»£æ–¹æ¡ˆã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šåŸºäºŽnnUNet-v2ï¼Œé€šè¿‡å¾ªçŽ¯è®­ç»ƒé‡‡æ ·æ¨¡åž‹æ£€æŸ¥ç‚¹è¿‘ä¼¼åŽéªŒï¼Œå®žçŽ°åˆ†å‰²å’Œä¸ç¡®å®šæ€§ä¼°è®¡ã€‚
3. å®žéªŒæˆ–æ•ˆæžœï¼šåœ¨è‚ºé³žç™Œæ•°æ®é›†ä¸Šï¼Œå¹³å‡Diceåˆ†æ•°0.805ï¼Œå¹³å‡IoU 0.709ï¼Œä¸ç¡®å®šæ€§å›¾ä¸Žåˆ†å‰²è¯¯å·®ç›¸å…³ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Accurate assessment of PD-L1 expression is critical for guiding immunotherapy, yet current immunohistochemistry (IHC) based methods are resource-intensive. We present nnUNet-B: a Bayesian segmentation framework that infers PD-L1 expression directly from H&E-stained histology images using Multimodal Posterior Sampling (MPS). Built upon nnUNet-v2, our method samples diverse model checkpoints during cyclic training to approximate the posterior, enabling both accurate segmentation and epistemic uncertainty estimation via entropy and standard deviation. Evaluated on a dataset of lung squamous cell carcinoma, our approach achieves competitive performance against established baselines with mean Dice Score and mean IoU of 0.805 and 0.709, respectively, while providing pixel-wise uncertainty maps. Uncertainty estimates show strong correlation with segmentation error, though calibration remains imperfect. These results suggest that uncertainty-aware H&E-based PD-L1 prediction is a promising step toward scalable, interpretable biomarker assessment in clinical workflows.

